# A Long-Term Extension Study of JNJ-77242113 in Participants with Moderate-to-Severe Plaque Psoriasis

Submission date	<b>Recruitment status</b> No longer recruiting	<ul><li>Prospectively registered</li></ul>			
03/08/2022		☐ Protocol			
Registration date 11/10/2022	Overall study status Completed	Statistical analysis plan			
		[X] Results			
Last Edited	Condition category	[] Individual participant data			
09/08/2024	Skin and Connective Tissue Diseases				

### Plain English summary of protocol

Background and study aims

Plaque psoriasis is a common, chronic, inflammatory condition, affecting about 3.5 million patients in the United States, European Union, and Japan. Despite advanced treatment options, large numbers of patients are not receiving these therapies. There is a need for safer options, fewer injections, and more effective oral medications. Janssen has an investigational drug called JNJ-77242113, which targets immune responses in the body and skin that impact diseases, such as psoriasis. It is hoped that targeting immune response processes may lead to less inflammation and a reduction in psoriasis disease activity.

This study is a follow-on trial of 77242113PSO2001 (https://www.isrctn.com/ISRCTN76915275), which is designed to evaluate long-term efficacy and safety of the investigational drug JNJ-77242113 in adults with moderate to severe plaque psoriasis.

#### Who can participate?

Patients who have completed the week 16 weeks in the study 77242113PSO2001 and who, in the opinion of the investigator, may benefit from inclusion in this long-term extension study.

#### What does the study involve?

This is a long-term extension study of JNJ-77242113 in eligible participants who completed the Week 16 visit of the originating 77242113PSO2001 study. All participants will receive active JNJ-77242113 study medication. The total study duration will be up to 40 weeks which will include:

- 1. A 36-week treatment period
- 2. A 4-week safety follow-up period after the last study intervention administration

Safety will be assessed by clinical safety laboratory assessments, electrocardiograms (ECGs), vital signs, physical examinations, and monitoring adverse events (AEs) throughout the study.

What are the possible benefits and risks of participating?

Possible benefits for patients taking JNJ-77242113 include improvements in plaque psoriasis symptoms based on current scientific theory. Only patients who may benefit from such drug

treatment (i.e., with specific disease characteristics identified by study investigators) are eligible for study inclusion. Such patient participation may help other psoriasis patients in the future.

Study participants also may experience some benefits not due to receiving the study drug, but instead due to regular visits, assessments, and overall health monitoring. Long-term benefits, however, are not guaranteed to happen and there may not be any benefit to participants by being in this study.

Not all possible side effects and risks related to JNJ-77242113 are known, such that unexpected side effects may arise or be life-threatening.

A participant information sheet (which will be signed by every participant agreeing to participate in the study) includes a detailed section outlining all known risks/side effects to study participants.

To minimize any study-associated risks participants are frequently reviewed at every visit for side effects and adverse events and participants are educated to report any such problems to the study staff without delay.

Any serious adverse events that are reported to the sponsor are thoroughly reviewed by a specialist drug safety team and the sponsor has implemented an Independent Data Review Committee.

Where is the study run from?

Janssen-Cilag International NV (Belgium) is the sponsor for this study. The study will be run at multiple healthcare locations both within the UK and around the world.

When is the study starting and how long is it expected to run for? June 2022 to November 2023

Who is funding the study?

Janssen Research and Development, LLC (USA)

Who is the main contact? Sarah Currie, JanssenUKRegistryQueries@its.jnj.com

# **Contact information**

# Type(s)

Scientific

#### Contact name

Dr Medical Information and Product Information Enquiry

#### Contact details

50-100 Holmers Farm Way High Wycombe United Kingdom HP12 4DP +44 (0)800 731 8450 medinfo@its.jnj.com

#### Type(s)

Principal investigator

#### Contact name

Dr Andrew Pink

#### Contact details

Guy's Hospital Great Maze Pond London United Kingdom London

# Additional identifiers

#### Clinical Trials Information System (CTIS)

2021-004320-16

#### Integrated Research Application System (IRAS)

1005014

#### ClinicalTrials.gov (NCT)

NCT05364554

#### Protocol serial number

IRAS 1005014, 77242113PSO2002, CPMS 52237

# Study information

#### Scientific Title

A Phase 2b Multicenter, Long-Term Extension, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis.

#### Acronym

**FRONTIER 2** 

#### Study objectives

Main objectives:

1. To evaluate long-term clinical response of JNJ-77242113 treatment in participants with moderate-to-severe plaque psoriasis

#### Secondary objectives:

- 1. To evaluate and assess additional long-term clinical response of JNJ-77242113 treatment in participants with moderate-to-severe plaque psoriasis
- 2. To evaluate and assess the effect of JNJ-77242113 treatment on patient-reported psoriasis severity in participants with moderate-to-severe plaque psoriasis
- 3. To evaluate and assess the safety and tolerability of JNJ-77242113 in participants with moderate-to-severe plaque psoriasis

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Approved 03/08/2022, South Central - Berkshire B Research Ethics Committee (Meeting held by video-conference via Zoom; +44 (0)207 104 8253, +44 (0)207 104 8068, +44 (0)207 104 8276; berkshireb.rec@hra.nhs.uk), ref: 22/SC/0224

#### Study design

Multicentre, long-term extension, double-blind, dose-ranging, parallel group, randomized interventional study

### Primary study design

Interventional

#### Study type(s)

Treatment

#### Health condition(s) or problem(s) studied

Plaque psoriasis

#### **Interventions**

The total duration of this study is up to 40 weeks which includes a 36-week treatment period, and a 4-week safety follow-up period. Participants will continue to receive the dose randomly assigned by the online interactive web randomisation system tool from the preceding study (77242113PSO2001).

Those participants assigned to the placebo treatment arm in the preceding study will be assigned to an active treatment arm in this study. Each active cohort group will also receive placebo to maintain blinding of dose regimens throughout the trial:

- 1. Group 1 will receive dose 1 of JNJ-77242113 once daily and placebo
- 2. Group 2 will receive dose 2 of JNJ-77242113 once daily and placebo
- 3. Group 3 will receive dose 3 of JNJ-77242113 once daily and placebo
- 4. Group 4 will receive dose 1 of JNJ-77242113 twice daily and placebo
- 5. Group 5 will receive dose 3 of JNJ-77242113 twice daily and placebo
- 6. Group 6 will receive dose 3 of JNJ-77242113 once daily and placebo

#### Intervention Type

Drug

#### Phase

Phase II

# Drug/device/biological/vaccine name(s)

JNJ-77242113

#### Primary outcome(s)

Percentage of participants achieving Psoriasis Area Severity Index (PASI) 75 score (≥75% improvement in PASI from baseline of the originating study [77242113PSO2001]) at Week 36. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk,

upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.

#### Key secondary outcome(s))

- 1. Percentage of participants achieving PASI 90 score (≥90% improvement in PASI from baseline of the originating study [77242113PSO2001]) at week 36
- 2. Percentage of participants achieving PASI 100 score (≥100% improvement in PASI from baseline of the originating study [77242113PSO2001]) at week 36
- 3. Change from baseline of the originating study (77242113PSO2001) in PASI Total Score at Week 36
- 4. Percentage of participants achieving an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) determined at Week 36. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
- 5. Change from baseline of originating study (77242113PSO2001) in Psoriasis Symptoms and Signs Diary (PSSD) Symptoms Scores reported at Week 36. The PSSD includes a patient-reported outcome (PRO) questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two subscores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
- 6. Change from baseline of originating study (77242113PSO2001) in Psoriasis Symptoms and Signs Diary (PSSD) Signs Scores reported at Week 36
- 7. Percentage of participants achieving PSSD Symptoms Score of 0 at Week 36 among participants with a baseline (in the originating study 77242113PSO2001) symptoms score ≥1 8. Percentage of participants achieving PSSD Signs Score of 0 at Week 36 among participants with a baseline (in the originating study 77242113PSO2001) signs score ≥1
- 9. Number of participants with Adverse Events (AEs) monitored up to Week 40. An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
- 10. Number of participants with Serious Adverse Events (SAEs) monitored up to Week 40. SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.

# Completion date

13/11/2023

# **Eligibility**

### Key inclusion criteria

- 1. Must have completed the Week 16 visit in Protocol 77232114PSO2001
- 2. In the opinion of the investigator, may benefit from inclusion in this long-term extension (LTE)

study

- 3. Must agree to avoid prolonged sun exposure and avoid the use of tanning booths or other ultraviolet light sources during the study
- 4. Must agree to discontinue all topical therapies that could affect psoriasis or the psoriasis area severity index (PASI) or Investigator's global assessment (IGA) evaluation, other than nonmedicated emollient and salicylic acid shampoos, prior to first administration of study intervention.
- 5. Agree not to receive a live virus or live bacterial vaccination during the study, or within 4 weeks after the last administration of the study intervention

#### Participant type(s)

**Patient** 

#### Healthy volunteers allowed

No

#### Age group

Adult

#### Sex

Αll

#### Total final enrolment

227

#### Key exclusion criteria

- 1. Was permanently discontinued from study intervention in Protocol 77242113PSO2001 for any reason
- 2. Has received any biologic therapy or experimental therapy since completion of the originating study 77242113PSO2001
- 3. Has received any live virus or bacterial vaccination within 12 weeks before the first administration of study intervention
- 4. Has received the bacille Clamette-Guerin (BCG) vaccine within 12 months of the first administration of study intervention
- 5. Currently has hepatitis B surface antigen (HBsAg) or hepatitis C antibody (antiHCV) positive, or has another clinically active liver disease, or tests positive for HBsAg or anti-HCV

#### Date of first enrolment

10/06/2022

#### Date of final enrolment

06/02/2023

# Locations

#### Countries of recruitment

United Kingdom

Canada



Study participating centre Skin Centre for Dermatology

775 Monaghan Road Peterborough Canada K9J 5K2

H2H2B5

France

Germany

Study participating centre
Dr. Chih-ho Hong Medical Inc.
15300 105 Ave
Surrey
Canada
V3R 6A7

Study participating centre DermEdge Research 333 Lakeshore Road West Mississauga Canada L4Y 4C5

# Study participating centre K. Papp Clinical Research

135 Union Street East Waterloo Canada N2J 1C4

Study participating centre
Dermatology Research Institute Inc.
8500 Blackfoot Trail SE
Calgary
Canada
T2J 7E1

# Study participating centre XLR8 Medical Research 2425 Tecumseh Road East

Windsor
Canada
N8W 1E6

# Study participating centre Dermatrials Research

25 Charlton Avenue East Hamilton Canada L8N 1Y2

# Study participating centre Universitatsklinikum Carl Gustav Carcus Dresden

Fetscherstr. 74 Dresden Germany 1307

### Study participating centre MensingDerma research GmbH Heegbarg 4 Hamburg

# Study participating centre Universitatsklinikum Schleswig-Holstein - Kiel

Arnold-Heller-Str. 3, Haus 19 Kiel Germany 24105

# Study participating centre Praxis für Dermatologie und Venerologie

Hauptstrasse 36a Dresden Germany 1097

### Study participating centre Rothhaar Studien GmbH

Dermatologisches Studienzentrum Berlin Germany 10783

# Study participating centre Hautarztpraxis

Annenstraße 151 Witten Germany 58453

### Study participating centre Uniklinik Münster -Klinik u. Pol. f. Hautkrankheiten

Von-Esmarch-Straße 58 Munster Germany 48149

# Study participating centre

### Niesmann & Othlinghaus GbR

Alleestraße 80 Bochum Germany 44793

# Study participating centre Universitatsklinikum Frankfurt

Theodor-Stern-Kai 7 Frankfurt am Main Germany 60590

### Study participating centre Universitätsklinikum Heidelberg Im Neuenheimer

Feld 440 Heidelberg Germany 69120

# Study participating centre Gemeinschaftspraxis Scholz/Sebastian/Schilling

Am Bahnhof 1 Mahlow Germany 15831

# Study participating centre

ISA - Interdisciplinary Study Association GmbH Rankestrasse 34 Berlin Germany 10789

# Study participating centre

Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Langenbeckstrasse 1 Mainz Germany 55131

# Study participating centre Fachklinik Bad Bentheim

Am Bade 1 Bad Bentheim Germany 48455

# Study participating centre Rosenpark Research GmbH

Rheinstrasse 14 Darmstadt Germany 64283

# Study participating centre Universitatsklinikum Bonn

Klinik und Poliklinik für Dermatologie und Allergologie Bonn Germany 53127

# Study participating centre Derma-Study-Center Friedrichshafen GmbH

Charlottenstrasse 12/1 Friedrichshafen Germany 88045

# Study participating centre Hosp. Univ. I Politecni La Fe

106 Avinguda de Fernando Abril Martorell Valencia Spain 46026

### Study participating centre Hosp. Univ. 12 De Octubre Avda. Cordoba sn

Madrid

# Study participating centre Hosp. Univ. Germans Trias I Pujol

Carretera de Canyet s/n Badalona Spain 8916

# Study participating centre

Hosp. De Manises

Av. de la Generalitat Valenciana, 50 Valencia Spain 46940

# Study participating centre Hosp. Univ. De Cruces

Plaza de Cruces, s/n Barakaldo Spain 48903

# Study participating centre Hosp. Reina Sofia

C/ Menéndez Pidal s/n Córdoba Spain 14004

# Study participating centre Hosp. Univ. De Basurto

Avenida de Montevideo, 18 Bilbao Spain 48013

# Study participating centre

#### HIA Sainte Anne

2 boulevard Sainte Anne Toulon France 83800

# Study participating centre Hopital Charles Nicolle

1 rue de Germont Rouen France 76031

# Study participating centre Centre Hospitalier Le Mans

194 Avenue Rubillard Le Mans France 72037

### Study participating centre Guy's and St Thomas' NHS Foundation Trust

Great Maze Pond London United Kingdom SE1 9RT

# Study participating centre University Hospital Southampton NHS Foundation Trust

Tremona Road Southampton United Kingdom SO16 6YD

# Study participating centre

**Kume Clinic** 1-65-2, Otorihigashimachi, Nishi Ku Osaka Fu Japan 593-8324

# Study participating centre Sapporo Skin Clinic

2-1-1 Minami-3Jo Nishi Sapporo Japan 060-0063

# Study participating centre Takagi Dermatology Clinic

Nishi-sanjo Minami 4-16 Obihiro-shi Japan 080-0013

# Study participating centre Nomura Dermatology Clinic

4-27-14 tanmachi Yokohama Japan 221-0825

# Study participating centre Shizuoka Prefectural General Hospital

4-27-1, Kitaando, Aoi-ku Shizuoka Japan 420-8527

# Study participating centre Shirasaki Dermatology Clinic

3-5-33 Ekinan Takaoka Japan 933-0871

# Study participating centre Toyama Prefectural Central Hospital

2-2-78 Nishinagae Toyama-shi Toyama

# Study participating centre Seoul National University Bundang Hospital

82, Gumi-ro 173beon-gil Gyeonggi-do Korea, South 13620

### Study participating centre Konkuk University Medical Center

120-1 NeunGdong-ro, Gwangjin-Gu Seoul Korea, South 5030

# Study participating centre Pusan National University Hospital

179 Gudeok-Ro Busan Korea, South 49241

# Study participating centre KyungHee University Hospital

23 Kyungheedae-Ro Seoul Korea, South 102-1703

# Study participating centre Asan Medical Center

88, Olympic-ro 43-gil, Songpa-gu, Seoul Korea, South 5505

# Study participating centre

### Seoul National University Hospital

101, Daehak-ro Seoul Korea, South 3080

### Study participating centre Severance Hospital, Yonsei University Health System

50-1, Yonsei-ro, Seodaemun-gu Seoul Korea, South 3722

# Study participating centre WROMEDICA

Mickiewicza 91 Wrocław Poland 51-685

# Study participating centre

DermoDent Centrum Medyczne Aldona Czajkowska Rafał Czajkowski s.c.

Tuberozy 3 Osielsko Poland 86031

### Study participating centre Nzoz Zdrowie Osteo-Medic

ul. Wiejska 81 Bialystok Poland 15-351

# Study participating centre Dermed Centrum Medyczne Sp. z o.o

ul. Piotrkowska 48 Lodz Poland 90-265

# Study participating centre Royalderm Agnieszka Nawrocka

K.Kieślowskiego 3B/3 Warszawa Poland 2962

# Study participating centre Klinika Ambroziak Estederm Sp. z o.o

Kosiarzy 9A Warszawa Poland 02-953

# Study participating centre NZOZ Specderm

Kardynala Stefana Wyszynskiego 10 lokal 11 Bialystok Poland 15-888

# Study participating centre Diamond Clinic Specjalistyczne Poradnie Lekarskie

Stefana Rogozinskiego 6/U3 Krakow Poland 31-559

# Study participating centre National Taiwan University Hospital

No.1, Changde Street Taipei City Taiwan 10048

# Study participating centre Chang-Gung Memorial Hospital, LinKou Branch

No.5 Fuxing street Taoyuan

# Study participating centre National Cheng Kung University Hospital

138 Sheng-Li Rd Tainan Taiwan 704

# Study participating centre Chang Gung Memorial Hospital

Kaohsiung Branch Kaohsiung Taiwan 83342

# Study participating centre Windsor Dermatology, PC

59 One Mile Rd Ext Ste G East Windsor United States of America 8520

# Study participating centre Arlington Dermatology

5301 Keystone Ct. Rolling Meadows United States of America 60008

# Study participating centre Modern Research Associates

9101 N. Central Expressway Dallas United States of America 75231

# Study participating centre

#### Renstar Medical Research

21 NE 1st Ave Ocala United States of America 34470

# Study participating centre University of Pittsburgh Department of Dermatology

3601 5th Ave Pittsburgh United States of America 15213

# Study participating centre Forcare Clinical Research, Inc.

15416 North Florida Avenue Tampa United States of America 33613

# Study participating centre Indiana Clinical Trial Center

824 Edwards Drive Plainfield United States of America 46168

# Study participating centre Oregon Dermatology and Research Center

2565 NW Lovejoy Portland United States of America 97210

# Study participating centre Center for Clinical Studies

1401 Binz Street Houston United States of America 77004

### Study participating centre Center for Clinical Studies

451 North Texas Avenue Webster United States of America 77598

# Study participating centre Hamzavi Dermatology

2950 Keewahdin Road Fort Gratiot United States of America 48059

### Study participating centre Vivida Dermatology

2110 East Flamingo Road, Suite 213 Las Vegas United States of America 89119

# Study participating centre Pacific Skin Institute

1495 River Park Drive Sacramento United States of America 95815

# Study participating centre Synergy Clinical Research

595 Buckingham Way San Francisco United States of America 94132

# Study participating centre Premier Clinical Research

324 South Sherman Spokane

# Sponsor information

#### Organisation

Janssen (Belgium)

#### **ROR**

https://ror.org/04yzcpd71

# Funder(s)

#### Funder type

Industry

#### **Funder Name**

Janssen Research and Development

### Alternative Name(s)

Janssen R&D, Janssen Research & Development, Janssen Research & Development, LLC, Janssen Research & Development LLC, Janssen Pharmaceutical Companies of Johnson & Johnson, Research & Development at Janssen, JRD, J&J PRD

#### **Funding Body Type**

Private sector organisation

#### **Funding Body Subtype**

For-profit companies (industry)

#### Location

United States of America

# **Results and Publications**

### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request. The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinicaltrials/transparency. As noted on this site, requests for access to the study data can be submitted through the Yale Open Data Access (YODA) Project site at yoda.yale.edu

# **IPD sharing plan summary** Available on request

# Study outputs

Study Outputs							
Output type		Details	Date created	Date added	Peer reviewed?	Patient- facing?	
HRA research	<u>summary</u>			28/06 /2023	No	No	
Other unpubl	shed results	Immunogenicity results have been redacted		09/08 /2024	No	No	
Participant inf sheet	ormation_	Participant information sheet	11/11/2025	11/11 /2025	No	Yes	